SG10201913768TA - Steroid derivative fxr agonist - Google Patents
Steroid derivative fxr agonistInfo
- Publication number
- SG10201913768TA SG10201913768TA SG10201913768TA SG10201913768TA SG10201913768TA SG 10201913768T A SG10201913768T A SG 10201913768TA SG 10201913768T A SG10201913768T A SG 10201913768TA SG 10201913768T A SG10201913768T A SG 10201913768TA SG 10201913768T A SG10201913768T A SG 10201913768TA
- Authority
- SG
- Singapore
- Prior art keywords
- fxr agonist
- steroid derivative
- derivative fxr
- steroid
- agonist
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/575—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of three or more carbon atoms, e.g. cholane, cholestane, ergosterol, sitosterol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J31/00—Normal steroids containing one or more sulfur atoms not belonging to a hetero ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J33/00—Normal steroids having a sulfur-containing hetero ring spiro-condensed or not condensed with the cyclopenta(a)hydrophenanthrene skeleton
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J33/00—Normal steroids having a sulfur-containing hetero ring spiro-condensed or not condensed with the cyclopenta(a)hydrophenanthrene skeleton
- C07J33/002—Normal steroids having a sulfur-containing hetero ring spiro-condensed or not condensed with the cyclopenta(a)hydrophenanthrene skeleton not condensed
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J43/00—Normal steroids having a nitrogen-containing hetero ring spiro-condensed or not condensed with the cyclopenta(a)hydrophenanthrene skeleton
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J43/00—Normal steroids having a nitrogen-containing hetero ring spiro-condensed or not condensed with the cyclopenta(a)hydrophenanthrene skeleton
- C07J43/003—Normal steroids having a nitrogen-containing hetero ring spiro-condensed or not condensed with the cyclopenta(a)hydrophenanthrene skeleton not condensed
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J9/00—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of more than two carbon atoms, e.g. cholane, cholestane, coprostane
- C07J9/005—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of more than two carbon atoms, e.g. cholane, cholestane, coprostane containing a carboxylic function directly attached or attached by a chain containing only carbon atoms to the cyclopenta[a]hydrophenanthrene skeleton
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J17/00—Normal steroids containing carbon, hydrogen, halogen or oxygen, having an oxygen-containing hetero ring not condensed with the cyclopenta(a)hydrophenanthrene skeleton
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J41/00—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring
- C07J41/0033—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005
- C07J41/0055—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005 the 17-beta position being substituted by an uninterrupted chain of at least three carbon atoms which may or may not be branched, e.g. cholane or cholestane derivatives, optionally cyclised, e.g. 17-beta-phenyl or 17-beta-furyl derivatives
- C07J41/0061—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005 the 17-beta position being substituted by an uninterrupted chain of at least three carbon atoms which may or may not be branched, e.g. cholane or cholestane derivatives, optionally cyclised, e.g. 17-beta-phenyl or 17-beta-furyl derivatives one of the carbon atoms being part of an amide group
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J41/00—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring
- C07J41/0033—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005
- C07J41/0094—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005 containing nitrile radicals, including thiocyanide radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J9/00—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of more than two carbon atoms, e.g. cholane, cholestane, coprostane
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201610061293 | 2016-01-28 | ||
| CN201610331759 | 2016-05-18 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG10201913768TA true SG10201913768TA (en) | 2020-03-30 |
Family
ID=59397430
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11201806348PA SG11201806348PA (en) | 2016-01-28 | 2017-01-25 | Steroid derivative fxr agonist |
| SG10201913768TA SG10201913768TA (en) | 2016-01-28 | 2017-01-25 | Steroid derivative fxr agonist |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11201806348PA SG11201806348PA (en) | 2016-01-28 | 2017-01-25 | Steroid derivative fxr agonist |
Country Status (16)
| Country | Link |
|---|---|
| US (2) | US10875888B2 (en) |
| EP (1) | EP3409684B1 (en) |
| JP (1) | JP6924765B2 (en) |
| KR (1) | KR20180100703A (en) |
| CN (1) | CN109071593B (en) |
| AU (2) | AU2017213032B2 (en) |
| BR (1) | BR112018015474A2 (en) |
| CA (1) | CA3012396C (en) |
| CL (1) | CL2018002009A1 (en) |
| IL (1) | IL260795B (en) |
| MX (1) | MX2018009175A (en) |
| MY (1) | MY196292A (en) |
| PH (1) | PH12018550120A1 (en) |
| SG (2) | SG11201806348PA (en) |
| WO (1) | WO2017129125A1 (en) |
| ZA (1) | ZA201805231B (en) |
Families Citing this family (31)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3215179A4 (en) | 2014-11-06 | 2018-07-25 | Enanta Pharmaceuticals, Inc. | Bile acid analogs an fxr/tgr5 agonists and methods of use thereof |
| AU2015353473A1 (en) | 2014-11-26 | 2017-06-08 | Enanta Pharmaceuticals, Inc. | Bile acid analogs as FXR/TGR5 agonists and methods of use thereof |
| US10208081B2 (en) | 2014-11-26 | 2019-02-19 | Enanta Pharmaceuticals, Inc. | Bile acid derivatives as FXR/TGR5 agonists and methods of use thereof |
| WO2016086115A1 (en) | 2014-11-26 | 2016-06-02 | Enanta Pharmaceuticals, Inc. | Tetrazole derivatives of bile acids as fxr/tgr5 agonists and methods of use thereof |
| MX2017010376A (en) | 2015-02-11 | 2017-12-20 | Enanta Pharm Inc | Bile acid analogs as fxr/tgr5 agonists and methods of use thereof. |
| SG10201910670RA (en) | 2015-03-31 | 2020-01-30 | Enanta Pharm Inc | Bile acid derivatives as fxr/tgr5 agonists and methods of use thereof |
| CN109071593B (en) * | 2016-01-28 | 2021-01-15 | 正大天晴药业集团股份有限公司 | Steroid derivative FXR agonist |
| WO2017147174A1 (en) | 2016-02-23 | 2017-08-31 | Enanta Pharmaceuticals, Inc. | Heteroaryl containing bile acid analogs as fxr/tgr5 agonists and methods of use thereof |
| US10364267B2 (en) | 2016-02-23 | 2019-07-30 | Enanta Pharmaceuticals, Inc. | Deuterated bile acid derivatives as FXR/TGR5 agonists and methods of use thereof |
| US10323060B2 (en) | 2016-02-23 | 2019-06-18 | Enanta Pharmaceuticals, Inc. | Benzoic acid derivatives of bile acid as FXR/TGR5 agonists and methods of use thereof |
| WO2018102418A1 (en) | 2016-11-29 | 2018-06-07 | Enanta Pharmaceuticals, Inc. | Process for preparation of sulfonylurea bile acid derivatives |
| US10472386B2 (en) | 2017-02-14 | 2019-11-12 | Enanta Pharmaceuticals, Inc. | Bile acid derivatives as FXR agonists and methods of use thereof |
| AU2018249950B2 (en) | 2017-04-07 | 2023-09-21 | Enanta Pharmaceuticals, Inc. | Process for preparation of sulfonyl carbamate bile acid derivatives |
| CN109134572A (en) * | 2017-06-19 | 2019-01-04 | 中国科学院上海药物研究所 | Chlolic acid derivatives and its preparation method and application |
| WO2019020067A1 (en) * | 2017-07-26 | 2019-01-31 | 正大天晴药业集团股份有限公司 | Method for preparing steroid derivative fxr agonist |
| WO2019020068A1 (en) * | 2017-07-26 | 2019-01-31 | 正大天晴药业集团股份有限公司 | Crystalline or amorphous form of steroid derivative fxr agonist, preparation method therefor and use thereof |
| CN107383139A (en) * | 2017-08-09 | 2017-11-24 | 杭州和泽医药科技有限公司 | The method that a kind of β cholanic acid new derivatives of 7 oxo of 3 α hydroxyls 5 prepare shellfish cholic acid difficult to understand |
| CN111247160B (en) * | 2017-11-02 | 2021-09-28 | 正大天晴药业集团股份有限公司 | Preparation method of cholic acid compound |
| CN107722000A (en) * | 2017-11-03 | 2018-02-23 | 中国药科大学 | The preparation of the berberinc derivate of 9-substitution and its medical usage |
| CN107987116B (en) * | 2018-01-17 | 2021-01-05 | 中国药科大学 | Chenodeoxycholic acid derivatives, preparation method and medical application thereof |
| CN116178473A (en) * | 2018-12-10 | 2023-05-30 | 江西青峰药业有限公司 | Preparation method of obeticholic acid |
| MX2022000742A (en) | 2019-07-18 | 2022-02-14 | Enyo Pharma | Method for decreasing adverse-effects of interferon. |
| CN110878113B (en) * | 2019-11-07 | 2021-02-02 | 成都贝诺科成生物科技有限公司 | Cholic acid derivative with antibacterial activity and medicinal composition thereof |
| KR20220128402A (en) | 2020-01-15 | 2022-09-20 | 인쎄름 (엥스띠뛰 나씨오날 드 라 쌍떼 에 드 라 흐쉐르슈 메디깔) | Use of an FXR agonist to treat infection by hepatitis D virus |
| JP2024502673A (en) | 2021-01-14 | 2024-01-22 | ウエヌイグレックオ・ファーマ | Synergistic effect of FXR agonist and IFN for treatment of HBV infection |
| TW202308629A (en) | 2021-04-28 | 2023-03-01 | 法商Ｅｎｙｏ製藥公司 | Strong potentiation of tlr3 agonists effects using fxr agonists as a combined treatment |
| CN113861258A (en) * | 2021-09-05 | 2021-12-31 | 中国海洋大学 | Method for synthesizing sargasterol |
| KR20230043773A (en) * | 2021-09-24 | 2023-03-31 | (주)샤페론 | Pharmaceutical composition for preventing, improving or treating non-alcoholic steatohepatitis, liver fibrosis comprising inflammasome inhibitor compound as an active ingredient |
| WO2023048528A1 (en) * | 2021-09-24 | 2023-03-30 | (주)샤페론 | Pharmaceutical composition comprising inflammasome inhibitor as active ingredient for prevention, alleviation, or treatment of atopic dermatitis |
| WO2023233346A1 (en) * | 2022-06-01 | 2023-12-07 | Precision Bio-Therapeutics S.R.L. | Cholesterol derivatives and their uses |
| CN116497082B (en) * | 2023-06-27 | 2023-09-29 | 华南理工大学 | Method for synthesizing 3 alpha, 7 alpha, 24R-trihydroxy cholesterol by chemical-enzymatic method |
Family Cites Families (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2002532729A (en) | 1998-12-23 | 2002-10-02 | グラクソ グループ リミテッド | Assay for nuclear receptor ligands |
| USRE48286E1 (en) * | 2001-03-12 | 2020-10-27 | Intercept Pharmaceuticals, Inc. | Steroids as agonists for FXR |
| EP1568706A1 (en) * | 2004-02-26 | 2005-08-31 | Intercept Pharmaceuticals, Inc. | Novel steroid agonist for FXR |
| KR20150004894A (en) * | 2012-05-01 | 2015-01-13 | 카타베이시스 파마슈티칼즈, 인코포레이티드 | Fatty acid conjugates of statin and fxr agonists； compositions and method of uses |
| JP6705808B2 (en) * | 2014-08-20 | 2020-06-03 | エフ．ホフマン−ラ ロッシュ アーゲー | In vitro method and apparatus for analyzing the behavior of substances in a simulated physiological environment |
| AU2015353473A1 (en) * | 2014-11-26 | 2017-06-08 | Enanta Pharmaceuticals, Inc. | Bile acid analogs as FXR/TGR5 agonists and methods of use thereof |
| US10208081B2 (en) * | 2014-11-26 | 2019-02-19 | Enanta Pharmaceuticals, Inc. | Bile acid derivatives as FXR/TGR5 agonists and methods of use thereof |
| WO2016086134A1 (en) | 2014-11-26 | 2016-06-02 | Enanta Pharmaceuticals, Inc. | Bile acid derivatives as fxr/tgr5 agonists and methods of use thereof |
| SG10201910670RA (en) * | 2015-03-31 | 2020-01-30 | Enanta Pharm Inc | Bile acid derivatives as fxr/tgr5 agonists and methods of use thereof |
| CN107250150B (en) | 2015-04-28 | 2019-11-22 | 江苏豪森药业集团有限公司 | Chlolic acid derivatives and preparation method thereof and medical usage |
| WO2016173493A1 (en) * | 2015-04-28 | 2016-11-03 | Shanghai De Novo Pharmatech Co. Ltd. | Sulfonylaminocarbonyl derivative, pharmaceutical composition and uses thereof |
| CN109071593B (en) * | 2016-01-28 | 2021-01-15 | 正大天晴药业集团股份有限公司 | Steroid derivative FXR agonist |
| US10323060B2 (en) | 2016-02-23 | 2019-06-18 | Enanta Pharmaceuticals, Inc. | Benzoic acid derivatives of bile acid as FXR/TGR5 agonists and methods of use thereof |
| CN109311446B (en) * | 2016-03-31 | 2021-10-22 | B/E航空公司 | System and method for protecting passengers in a tilt-mounted aircraft seat |
-
2017
- 2017-01-25 CN CN201780007715.1A patent/CN109071593B/en active Active
- 2017-01-25 KR KR1020187024701A patent/KR20180100703A/en active Search and Examination
- 2017-01-25 BR BR112018015474-1A patent/BR112018015474A2/en active Search and Examination
- 2017-01-25 CA CA3012396A patent/CA3012396C/en active Active
- 2017-01-25 SG SG11201806348PA patent/SG11201806348PA/en unknown
- 2017-01-25 MY MYPI2018702594A patent/MY196292A/en unknown
- 2017-01-25 SG SG10201913768TA patent/SG10201913768TA/en unknown
- 2017-01-25 US US16/072,839 patent/US10875888B2/en active Active
- 2017-01-25 MX MX2018009175A patent/MX2018009175A/en unknown
- 2017-01-25 EP EP17743740.7A patent/EP3409684B1/en active Active
- 2017-01-25 AU AU2017213032A patent/AU2017213032B2/en active Active
- 2017-01-25 JP JP2018539427A patent/JP6924765B2/en active Active
- 2017-01-25 WO PCT/CN2017/072567 patent/WO2017129125A1/en active Application Filing
-
2018
- 2018-07-24 CL CL2018002009A patent/CL2018002009A1/en unknown
- 2018-07-25 PH PH12018550120A patent/PH12018550120A1/en unknown
- 2018-07-26 IL IL260795A patent/IL260795B/en active IP Right Grant
- 2018-08-03 ZA ZA2018/05231A patent/ZA201805231B/en unknown
-
2020
- 2020-10-13 US US17/069,691 patent/US11667667B2/en active Active
-
2021
- 2021-03-31 AU AU2021202018A patent/AU2021202018B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| US11667667B2 (en) | 2023-06-06 |
| AU2021202018B2 (en) | 2022-04-07 |
| CL2018002009A1 (en) | 2018-11-05 |
| ZA201805231B (en) | 2022-03-30 |
| CN109071593B (en) | 2021-01-15 |
| IL260795B (en) | 2021-04-29 |
| US10875888B2 (en) | 2020-12-29 |
| CA3012396C (en) | 2024-03-26 |
| EP3409684B1 (en) | 2024-01-03 |
| PH12018550120A1 (en) | 2019-03-18 |
| EP3409684A4 (en) | 2019-10-09 |
| WO2017129125A1 (en) | 2017-08-03 |
| MY196292A (en) | 2023-03-24 |
| SG11201806348PA (en) | 2018-08-30 |
| BR112018015474A2 (en) | 2018-12-18 |
| US20210040140A1 (en) | 2021-02-11 |
| AU2017213032B2 (en) | 2021-01-07 |
| KR20180100703A (en) | 2018-09-11 |
| AU2021202018A1 (en) | 2021-04-29 |
| JP2019503392A (en) | 2019-02-07 |
| AU2017213032A1 (en) | 2018-08-30 |
| EP3409684A1 (en) | 2018-12-05 |
| MX2018009175A (en) | 2018-11-29 |
| CN109071593A (en) | 2018-12-21 |
| CA3012396A1 (en) | 2017-08-03 |
| JP6924765B2 (en) | 2021-08-25 |
| US20190382437A1 (en) | 2019-12-19 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ZA201805231B (en) | Steroid derivative fxr agonist | |
| HK1257647A1 (en) | Methods for using fxr agonists | |
| HK1257649A1 (en) | Methods for using fxr agonists | |
| EP3650449A4 (en) | Fxr receptor agonist | |
| EP3116878A4 (en) | Fxr agonists and methods for making and using | |
| HK1257648A1 (en) | Methods for using fxr agonists | |
| EP3321438A4 (en) | Flush toilet device | |
| HK1249900A1 (en) | Morphinan derivative | |
| IL277068B (en) | Cellular-based method for determining the potency of defibrotide | |
| PL3194670T3 (en) | Device for toilets | |
| ZA201604927B (en) | Aminopyrazolone derivative | |
| EP3336267A4 (en) | Flush toilet device | |
| EP3105207A4 (en) | Gpr142 agonist compounds | |
| GB2554118B (en) | Doorstop apparatus | |
| GB2557191B (en) | Toilet assembly and method for its operation | |
| ZA201700664B (en) | Azole benzene derivative and crystalline form thereof | |
| GB201620226D0 (en) | Toilet assembly and method for its operation | |
| GB201513175D0 (en) | An improved toilet | |
| EP3135669A4 (en) | Oxazolidine-based compound and selective androgen receptor agonist comprising same |